Unity Biotechnology Inc

Unity Biotechnology — Technical Presentation (April 2023)

21 slides from Unity Biotechnology's technical presentation, Apr 24, 2023

  1. Slide 1: UBX1325 Phase 2 BEHOLD Study in DME 48 Week Top Line Results

    NASDAQ: UBX UBX1325 Phase 2 BEHOLD Study in DME 48 Week Top Line Results Robert Bhisitkul, M.D., Ph.D. Professor of Ophthalmology, UCSF Anirvan Ghosh, CEO Jamie Dananberg, CMO Lynne Sullivan, CFO Exhibit 99.2

  2. Slide 2: Special Note Regarding Forward-Looking Statements

    Special Note Regarding Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to Unity Biotechnology Inc.’s (“UNITY’s”) understanding of cellular senescence and the role it plays in diseases of aging, the pote

  3. Slide 3: Top Line Results, Mechanism of Action, Clinical Development Plan

    Top Line Results UBX1325 Mechanism of Action Clinical Development Plan

  4. Slide 4: UBX1325 Led to Statistically Significant and Clinically Meaningful Improvement in Visual Acuity in DME

    UBX1325 Led to a Statistically Significant and Clinically Meaningful Improvement in Visual Acuity in Patients with Diabetic Macular Edema Through 48 Weeks A single dose of UBX1325 demonstrated: UBX1325-treated patients had a significant improvement in BCVA of +6.2 ETDRS letters from baseline and +5.

  5. Slide 5: UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells

    UNITY Is Developing Senolytic Medicines to Eliminate Senescent Cells to Restore Vascular Health and Improve Vision UNITY illustration 24 April 2023 DME: Increased senescence burden Poor barrier function Production of inflammatory factors Loss of retinal function DME treated with Senolytic (intended

  6. Slide 6: UBX1325 Clinical Program Overview

    UBX1325 Clinical Program Overview Safety & Tolerability Safety & Efficacy 2020 2021 2022 2023 Phase 1 ENVISION: Phase 2 nAMD Study BEHOLD: Phase 2 DME Study SAD 24-Week Follow-up nAMD 24 Week Follow-up SAD Study - up to 10 µg 4Q ‘21 1H ‘22 2H ‘22 Long-Term Extension DME Proof of Concept Study (First

  7. Slide 7: Context for 24wk DME Data After Anti-VEGF Effect Plateaued

    Context for 24wk DME Data: After Anti-VEGF Effect Has Plateaued, Patients Gain Approximately 1 Letter in Subsequent 6 Months on Aflibercept Treatment VISTA BLA 125387 Suppl 48, 25 Mar 2015 24 April 2023

  8. Slide 8: UBX1325 Ph2 BEHOLD Study 48-week data in patients with DME

    UBX1325 Ph2 BEHOLD Study 48-week data in patients with DME 24 April 2023

  9. Slide 9: BEHOLD Study Design, Patient Population, and Endpoints

    BEHOLD Study Design, Patient Population, and Endpoints Source: t_14_1_1 24 April 2023 Individuals with Diabetic Macular Edema Repeated anti-VEGF treatments (≥2 injections/6 months) – Actual: 4.1 injections in prior 6 months Residual retinal fluid (≥300 µm) – Actual: 439.6 µm Visual acuity deficit (7

  10. Slide 10: Patient characteristics at baseline were well balanced between groups

    Patient characteristics at baseline were well balanced between groups Source: t_14_1_2 24 April 2023 Parameter, Units (SD) Sham UBX1325 Age, Years 61.4 (9.09) 63.6 (9.33) HBA1c, % 7.4 (1.36) 8.0 (1.68) Diabetes Dx, Years 17.5 (10.53) 17.2 (11.41) DME Dx, Years 3.0 (2.32) 3.5 (3.60) BCVA, ETDRS lette

  11. Slide 11: Marked drop in need for anti-VEGF rescue beyond week 18 vs Sham

    UBX1325-treated patients had marked drop in need for anti-VEGF rescue beyond week 18 compared to Sham-treated patients through 48 weeks Source: f_km_plots_listings; f_km_plots 24 April 2023 * p = 0.0159 Log-Rank * Median Time to First Rescue Sham: 17.5 Weeks Efficacy analyses excluding and including

  12. Slide 12: Significant improvement in BCVA of 6.2 letters at 48 weeks

    * * * * * * * * * * * UBX1325-treated patients had a significant improvement in BCVA from baseline† of 6.2 letters at 48 weeks (excluding data post-rescue) Source: f_14_2_1_1; t_14_2_1_1 24 April 2023 * p < 0.05 vs. baseline BCVA CFBL (ETDRS Letters) UBX1325 Sham Delta Between Group p-value Week 24

  13. Slide 13: Significant visual acuity gains vs Sham based on last observation prior to rescue

    UBX1325-treated patients had significant visual acuity gains compared to Sham based on analysis of last observation prior to rescue or end of study† Source: f_14_2_1_35 24 April 2023 * Last observation carried forward (to rescue or end of study participation) † Supplemental Analysis Mean BCVA change

  14. Slide 14: Significant BCVA improvement from baseline at all timepoints including post-rescue data

    At all timepoints, UBX1325-treated patients had a statistically significant improvement in BCVA from baseline† (including post-rescue data) Source: f_14_2_1_13; t_14_2_1_2 24 April 2023 All points p < 0.05 vs. baseline except Sham Weeks 4, 24 and UBX Week 8 NS: not significant BCVA CFBL (ETDRS Lette

  15. Slide 15: 50% of UBX1325-treated patients gained at least letters of vision through 48 weeks

    50% of UBX1325-treated patients gained at least 5 letters of vision through 48 weeks, with over 20% gaining at least 10 letters (excluding post-rescue data) Source: t_14_2_4_1 24 April 2023

  16. Slide 16: CST remained stable in UBX1325 patients compared to worsening in Sham

    CST remained stable in UBX1325-treated patients compared to worsening in Sham patients (excluding post-rescue data) Source: f_14_2_1_2; t_14_2_1_3 24 April 2023 Sham: p < 0.15 vs BL all points except Weeks 1 and 48 UBX: All points not significantly different from baseline NS: not significant BCVA CF

  17. Slide 17: Mean CST lower in UBX1325 patients vs Sham at 48 weeks

    Mean CST was significantly lower in UBX1325-treated patients compared to Sham patients at 48 weeks (including post-rescue data) Source: f_14_2_1_14; t_14_2_1_4 24 April 2023 NS: not significant * * * * * * * p < 0.15 vs. BL BCVA CFBL (ETDRS Letters) UBX1325 Sham Delta Between Group p-value Week 24 -

  18. Slide 18: 53.1% of UBX1325 patients did not require anti-VEGF rescue through 48 weeks

    53.1% of UBX1325-treated patients did not require anti-VEGF rescue through 48 weeks compared to 21.9% of Sham patients Source: f_14_2_4_1; t_14_2_2_1 24 April 2023 UBX vs. Sham p = 0.0096 Rescue Criteria (Either) Decrease of 10 ETDRS or more letters from any peak value Increase in CST of 75 µm or mo

  19. Slide 19: UBX1325 demonstrated favorable safety and tolerability with no intraocular inflammation

    UBX1325 demonstrated a favorable overall safety and tolerability profile with no instances of intraocular inflammation Source: t_14_3_1_1 24 April 2023 Parameter, No. of Patients Sham (N = 33) UBX1325 10 µg (N = 32) Subjects with at least one TEAE 31 (93.9) 26 (81.3) Related TEAE 3 (9.1) 6 (18.8) Gr

  20. Slide 20: Summary of Findings and Concordance of Evidence Supporting Treatment Effect

    Summary of Findings and Concordance of Evidence Supporting a Treatment Effect of UBX1325 in Diabetic Macular Edema Had a generally favorable safety and tolerability profile with no intraocular inflammation Led to a majority of patients achieving a rescue-free interval of at least 48 weeks and may re

  21. Slide 21: Q&A

    BIOTECHNOLOGY Q&A

Unity Biotechnology — Technical Presentation (April 2023) on 6ix